metformin has been researched along with Choline Deficiency in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Choline Deficiency: A condition produced by a deficiency of CHOLINE in animals. Choline is known as a lipotropic agent because it has been shown to promote the transport of excess fat from the liver under certain conditions in laboratory animals. Combined deficiency of choline (included in the B vitamin complex) and all other methyl group donors causes liver cirrhosis in some animals. Unlike compounds normally considered as vitamins, choline does not serve as a cofactor in enzymatic reactions. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)." | 7.73 | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006) |
| "To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)." | 3.73 | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Okishio, S | 1 |
| Yamaguchi, K | 1 |
| Ishiba, H | 1 |
| Tochiki, N | 1 |
| Yano, K | 1 |
| Takahashi, A | 1 |
| Kataoka, S | 1 |
| Okuda, K | 1 |
| Seko, Y | 1 |
| Liu, Y | 1 |
| Fujii, H | 1 |
| Takahashi, D | 1 |
| Ito, Y | 1 |
| Kamon, J | 1 |
| Umemura, A | 1 |
| Moriguchi, M | 1 |
| Yasui, K | 1 |
| Okanoue, T | 1 |
| Itoh, Y | 1 |
| Katsura, A | 1 |
| Morishita, A | 1 |
| Iwama, H | 1 |
| Tani, J | 1 |
| Sakamoto, T | 1 |
| Tatsuta, M | 1 |
| Toyota, Y | 1 |
| Fujita, K | 1 |
| Kato, K | 1 |
| Maeda, E | 1 |
| Nomura, T | 1 |
| Miyoshi, H | 1 |
| Yoneyama, H | 1 |
| Himoto, T | 1 |
| Fujiwara, S | 1 |
| Kobara, H | 1 |
| Mori, H | 1 |
| Niki, T | 1 |
| Ono, M | 1 |
| Hirashima, M | 1 |
| Masaki, T | 1 |
| Assy, N | 1 |
| Grozovski, M | 1 |
| Bersudsky, I | 1 |
| Szvalb, S | 1 |
| Hussein, O | 1 |
3 other studies available for metformin and Choline Deficiency
| Article | Year |
|---|---|
PPARĪ± agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat.
Topics: Alanine Transaminase; Amino Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; A | 2020 |
MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Choline Deficiency; Cluster Analysis; Diet; Disease Models, Animal; Gene Expression; Gene E | 2015 |
Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Topics: Animals; Anticholesteremic Agents; Azetidines; Choline Deficiency; Drug Therapy, Combination; Ezetim | 2006 |